{"id":60276,"date":"2024-10-07T12:05:08","date_gmt":"2024-10-07T12:05:08","guid":{"rendered":"https:\/\/english.saigonbiz.com.vn\/2024\/10\/07\/proqr-highlights-upcoming-presentation-at-20th-annual-meeting-of-the-oligonucleotide-therapeutics-society\/"},"modified":"2024-10-07T12:05:08","modified_gmt":"2024-10-07T12:05:08","slug":"proqr-highlights-upcoming-presentation-at-20th-annual-meeting-of-the-oligonucleotide-therapeutics-society","status":"publish","type":"post","link":"https:\/\/english.saigonbiz.com\/vn\/proqr-highlights-upcoming-presentation-at-20th-annual-meeting-of-the-oligonucleotide-therapeutics-society\/","title":{"rendered":"ProQR Highlights Upcoming Presentation at 20th Annual Meeting of the Oligonucleotide Therapeutics Society"},"content":{"rendered":"<div>\n<p>LEIDEN, Netherlands &amp; CAMBRIDGE, Mass., Oct.  07, 2024  (GLOBE NEWSWIRE) &#8212; ProQR Therapeutics NV (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies, today announced it will present preclinical data for its proprietary Axiomer&#x2122; RNA editing technology platform and its AX-0810 pipeline program for cholestatic diseases targeting NTCP at the 20th Annual Meeting of the Oligonucleotide Therapeutics Society, October 6-9, 2024, in Montreal, QC, Canada.<\/p>\n<p>Gerard Platenburg, co-founder and Chief Scientific Officer at ProQR, will present on Tuesday, October 8 at 10:15 am ET (Session IV: DNA\/RNA Editing).<\/p>\n<p>Oral presentation:<br \/>\u201cOligonucleotide guided RNA editing of <em>SLC10A1<\/em> (NTCP) as a therapeutic approach to lower bile acid re-uptake in cholestatic diseases\u201d<\/p>\n<p>Following OTS, the slide deck will be available via ProQR\u2019s website in the\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=80bdJdMdUShQI-m5Q86N8_wt3CcsO8xcVAABP7TY5p8nvJAd8ZjF4F-PO1KDDa53BL1CX_w2prqLOHlQo9CGFXVOLY-8Fb-gWlHieGEVPVok37_h2nowhUsqHQ1Kqr1yLEwaIYCYnUqXc_Zk-3zUiw==\" rel=\"nofollow noopener\" target=\"_blank\" title=\"Presentations and Publications\">Presentations and Publications<\/a> section.<\/p>\n<p><strong>About Axiomer&#x2122;<\/strong><\/p>\n<p>ProQR is pioneering a next-generation RNA base editing technology called Axiomer&#x2122;, which could potentially yield a new class of medicines for diverse types of diseases. Axiomer \u201cEditing Oligonucleotides\u201d, or EONs, mediate single nucleotide changes to RNA in a highly specific and targeted way using molecular machinery that is present in human cells called ADAR (Adenosine Deaminase Acting on RNA). Axiomer EONs are designed to recruit and direct endogenously expressed ADARs to change an Adenosine (A) to an Inosine (I) in the RNA \u2013 an Inosine is translated as a Guanosine (G) \u2013 correcting an RNA with a disease-causing mutation back to a normal (wild type) RNA, modulating protein expression, or altering a protein so that it will have a new function that helps prevent or treat disease. <\/p>\n<p><strong>About ProQR<\/strong><\/p>\n<p>ProQR Therapeutics is dedicated to changing lives through the creation of transformative RNA therapies. ProQR is pioneering a next-generation RNA technology called Axiomer&#x2122;, which uses a cell\u2019s own editing machinery called ADAR to make specific single nucleotide edits in RNA to reverse a mutation or modulate protein expression and could potentially yield a new class of medicines for both rare and prevalent diseases with unmet need. Based on our unique proprietary RNA repair platform technologies we are growing our pipeline with patients and loved ones in mind.<\/p>\n<p>Learn more about ProQR at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ddNdzor7ZLp9HkJD7UIbxtwrDLNyNTq4rZTk3t4ld250XddUAw8lA5GGkGa9_s48bg33_HenPstQJao8seUpbw==\" rel=\"nofollow noopener\" target=\"_blank\" title=\"\"><strong>www.proqr.com<\/strong><\/a>.<\/p>\n<p><strong>Forward Looking Statements for ProQR<\/strong><\/p>\n<p>This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as \u201ccontinue,\u201d &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;goal,&#8221; &#8220;intend,&#8221; &#8220;look forward to&#8221;, &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;should,&#8221; &#8220;will,&#8221; &#8220;would&#8221; and similar expressions. Such forward-looking statements include, but are not limited to, statements regarding our presentation at this conference, our Axiomer&#x2122; technology, including the continued development and advancement of our Axiomer platform, the therapeutic potential of our Axiomer RNA editing oligonucleotides and our ability to expand preclinical <em>in vivo<\/em> and <em>in vitro<\/em> data, the timing, progress and results of our preclinical studies and other development activities, including the release of data related thereto, and the potential of our technologies and product candidates. Forward-looking statements are based on management\u2019s beliefs and assumptions and on information available to management only as of the date of this press release. Our actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including, without limitation, the risks, uncertainties and other factors in our filings made with the Securities and Exchange Commission, including certain sections of our most recent annual report filed on Form 20-F. These risks and uncertainties include, among others, the cost, timing and results of preclinical studies and clinical trials and other development activities by us and our collaborative partners whose operations and activities may be slowed or halted shortage and pressure on supply and logistics on the global market; the likelihood of our preclinical and clinical programs being initiated and executed on timelines provided and reliance on our contract research organizations and predictability of timely enrollment of subjects and patients to advance our clinical trials and maintain their own operations; our reliance on contract manufacturers or suppliers to supply materials for research and development and the risk of supply interruption or delays from suppliers or contract manufacturers; the potential for future data to alter initial and preliminary results of early-stage clinical trials; the unpredictability of the duration and results of the regulatory review of applications or clearances that are necessary to initiate and continue to advance and progress our clinical programs; the ability to secure, maintain and realize the intended benefits of collaborations with partners, including the collaboration with Eli Lilly and Company; the possible impairment of, inability to obtain, and costs to obtain intellectual property rights; possible safety or efficacy concerns that could emerge as new data are generated in research and development; general business, operational, financial and accounting risks, and risks related to litigation and disputes with third parties; and risks related to macroeconomic conditions and market volatility resulting from global economic developments, geopolitical instability and conflicts. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, even if new information becomes available in the future, except as required by law.<\/p>\n<p><strong>ProQR Therapeutics N.V.<\/strong><\/p>\n<p><strong>Investor contact:<\/strong><br \/>Sarah Kiely<br \/>ProQR Therapeutics N.V.<br \/>T: +1 617 599 6228<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=C2Y8NDWptNd5nCXV0fm2LSC5UM2_5L_DU-2MSNOc5B-HDlacFaaYjiEROdVpombZ1GQnxWDNfNcOEKo-_w6-dNht_HAywrLWPppvgJOKIZ8=\" rel=\"nofollow noopener\" target=\"_blank\" title=\"\"><strong>skiely@proqr.com<\/strong><\/a><br \/>or<br \/>Peter Kelleher<br \/>LifeSci Advisors<br \/>T: +1 617 430 7579 <br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=bSReLdkfcnWHHGGl83nTa3rj4IQ5j6ZHmAz4OXUP0P_7x0mBF9BZoEUQEPBQ3mebgUfQ-eRK8eNvk06plqSyzdryK9Jky1T-kSwGkX6w65S_AjGlcyL1gdsRq5W2zVlN\" rel=\"nofollow noopener\" target=\"_blank\" title=\"\"><strong>pkelleher@lifesciadvisors.com<\/strong><\/a><\/p>\n<p><strong>Media contact:<\/strong><br \/>Robert Stanislaro<br \/>FTI Consulting<br \/>T: +1 212 850 5657<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=2588_vnSv7GvCdMwN-2YogcV96YgW2v-ikWymuHAwYrMXPLQ4UAJQcBwMKM_ZX9A5FSW1RpTQRw7eBJDhbDe6gqRrShAepjP30z-zk5Uuv5Z2ONN-7m5_8B120Vz0oH_2PpGReISpqetq4-2_UYBsg==\" rel=\"nofollow noopener\" target=\"_blank\" title=\"\"><strong>robert.stanislaro@fticonsulting.com<\/strong><\/a><\/p>\n<p><img decoding=\"async\" src=\"https:\/\/ml-eu.globenewswire.com\/media\/NTI4YmNkMTEtNTUwZi00YjBjLWI2M2QtYTMxZGFhYWI5OGMzLTEwMjI3NDA=\/tiny\/ProQR-Therapeutics-N-V-.png\" referrerpolicy=\"no-referrer-when-downgrade\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>LEIDEN, Netherlands &amp; CAMBRIDGE, Mass., Oct. 07, 2024 (GLOBE NEWSWIRE) &#8212; ProQR Therapeutics NV (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies, today announced it will present preclinical data for its proprietary Axiomer&#x2122; RNA editing technology platform and its AX-0810 pipeline program for cholestatic diseases targeting NTCP at the 20th [&#8230;]\n","protected":false},"author":1,"featured_media":60277,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-60276","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-pr-newswire"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v21.6 (Yoast SEO v21.6) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>ProQR Highlights Upcoming Presentation at 20th Annual Meeting of the Oligonucleotide Therapeutics Society - Biz and Live in Saigon<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/english.saigonbiz.com\/vn\/proqr-highlights-upcoming-presentation-at-20th-annual-meeting-of-the-oligonucleotide-therapeutics-society\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ProQR Highlights Upcoming Presentation at 20th Annual Meeting of the Oligonucleotide Therapeutics Society\" \/>\n<meta property=\"og:description\" content=\"LEIDEN, Netherlands &amp; CAMBRIDGE, Mass., Oct. 07, 2024 (GLOBE NEWSWIRE) &#8212; ProQR Therapeutics NV (Nasdaq: PRQR) (ProQR), a company dedicated t\" \/>\n<meta property=\"og:url\" content=\"https:\/\/english.saigonbiz.com\/vn\/proqr-highlights-upcoming-presentation-at-20th-annual-meeting-of-the-oligonucleotide-therapeutics-society\/\" \/>\n<meta property=\"og:site_name\" content=\"Biz and Live in Saigon\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/SaigonbizGroup\" \/>\n<meta property=\"article:published_time\" content=\"2024-10-07T12:05:08+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2024\/10\/ProQR-Therapeutics-N-V-.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1\" \/>\n\t<meta property=\"og:image:height\" content=\"1\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/proqr-highlights-upcoming-presentation-at-20th-annual-meeting-of-the-oligonucleotide-therapeutics-society\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/proqr-highlights-upcoming-presentation-at-20th-annual-meeting-of-the-oligonucleotide-therapeutics-society\/\"},\"author\":{\"name\":\"admin\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6\"},\"headline\":\"ProQR Highlights Upcoming Presentation at 20th Annual Meeting of the Oligonucleotide Therapeutics Society\",\"datePublished\":\"2024-10-07T12:05:08+00:00\",\"dateModified\":\"2024-10-07T12:05:08+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/proqr-highlights-upcoming-presentation-at-20th-annual-meeting-of-the-oligonucleotide-therapeutics-society\/\"},\"wordCount\":894,\"publisher\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\"},\"articleSection\":[\"Pr Newswire\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/proqr-highlights-upcoming-presentation-at-20th-annual-meeting-of-the-oligonucleotide-therapeutics-society\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/proqr-highlights-upcoming-presentation-at-20th-annual-meeting-of-the-oligonucleotide-therapeutics-society\/\",\"name\":\"ProQR Highlights Upcoming Presentation at 20th Annual Meeting of the Oligonucleotide Therapeutics Society - Biz and Live in Saigon\",\"isPartOf\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#website\"},\"datePublished\":\"2024-10-07T12:05:08+00:00\",\"dateModified\":\"2024-10-07T12:05:08+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/proqr-highlights-upcoming-presentation-at-20th-annual-meeting-of-the-oligonucleotide-therapeutics-society\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/english.saigonbiz.com\/vn\/proqr-highlights-upcoming-presentation-at-20th-annual-meeting-of-the-oligonucleotide-therapeutics-society\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/proqr-highlights-upcoming-presentation-at-20th-annual-meeting-of-the-oligonucleotide-therapeutics-society\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/english.saigonbiz.com\/vn\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"ProQR Highlights Upcoming Presentation at 20th Annual Meeting of the Oligonucleotide Therapeutics Society\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#website\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/\",\"name\":\"Biz and Live in Saigon\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/english.saigonbiz.com\/vn\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\",\"name\":\"SaigonBiz Media\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png\",\"contentUrl\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png\",\"width\":512,\"height\":512,\"caption\":\"SaigonBiz Media\"},\"image\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/SaigonbizGroup\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6\",\"name\":\"admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png\",\"contentUrl\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png\",\"caption\":\"admin\"},\"sameAs\":[\"https:\/\/english.saigonbiz.com\/vn\"],\"url\":\"https:\/\/english.saigonbiz.com\/vn\/profile\/admin\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"ProQR Highlights Upcoming Presentation at 20th Annual Meeting of the Oligonucleotide Therapeutics Society - Biz and Live in Saigon","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/english.saigonbiz.com\/vn\/proqr-highlights-upcoming-presentation-at-20th-annual-meeting-of-the-oligonucleotide-therapeutics-society\/","og_locale":"en_US","og_type":"article","og_title":"ProQR Highlights Upcoming Presentation at 20th Annual Meeting of the Oligonucleotide Therapeutics Society","og_description":"LEIDEN, Netherlands &amp; CAMBRIDGE, Mass., Oct. 07, 2024 (GLOBE NEWSWIRE) &#8212; ProQR Therapeutics NV (Nasdaq: PRQR) (ProQR), a company dedicated t","og_url":"https:\/\/english.saigonbiz.com\/vn\/proqr-highlights-upcoming-presentation-at-20th-annual-meeting-of-the-oligonucleotide-therapeutics-society\/","og_site_name":"Biz and Live in Saigon","article_publisher":"https:\/\/www.facebook.com\/SaigonbizGroup","article_published_time":"2024-10-07T12:05:08+00:00","og_image":[{"width":1,"height":1,"url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2024\/10\/ProQR-Therapeutics-N-V-.png","type":"image\/png"}],"author":"admin","twitter_card":"summary_large_image","twitter_misc":{"Written by":"admin","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/english.saigonbiz.com\/vn\/proqr-highlights-upcoming-presentation-at-20th-annual-meeting-of-the-oligonucleotide-therapeutics-society\/#article","isPartOf":{"@id":"https:\/\/english.saigonbiz.com\/vn\/proqr-highlights-upcoming-presentation-at-20th-annual-meeting-of-the-oligonucleotide-therapeutics-society\/"},"author":{"name":"admin","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6"},"headline":"ProQR Highlights Upcoming Presentation at 20th Annual Meeting of the Oligonucleotide Therapeutics Society","datePublished":"2024-10-07T12:05:08+00:00","dateModified":"2024-10-07T12:05:08+00:00","mainEntityOfPage":{"@id":"https:\/\/english.saigonbiz.com\/vn\/proqr-highlights-upcoming-presentation-at-20th-annual-meeting-of-the-oligonucleotide-therapeutics-society\/"},"wordCount":894,"publisher":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#organization"},"articleSection":["Pr Newswire"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/english.saigonbiz.com\/vn\/proqr-highlights-upcoming-presentation-at-20th-annual-meeting-of-the-oligonucleotide-therapeutics-society\/","url":"https:\/\/english.saigonbiz.com\/vn\/proqr-highlights-upcoming-presentation-at-20th-annual-meeting-of-the-oligonucleotide-therapeutics-society\/","name":"ProQR Highlights Upcoming Presentation at 20th Annual Meeting of the Oligonucleotide Therapeutics Society - Biz and Live in Saigon","isPartOf":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#website"},"datePublished":"2024-10-07T12:05:08+00:00","dateModified":"2024-10-07T12:05:08+00:00","breadcrumb":{"@id":"https:\/\/english.saigonbiz.com\/vn\/proqr-highlights-upcoming-presentation-at-20th-annual-meeting-of-the-oligonucleotide-therapeutics-society\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/english.saigonbiz.com\/vn\/proqr-highlights-upcoming-presentation-at-20th-annual-meeting-of-the-oligonucleotide-therapeutics-society\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/english.saigonbiz.com\/vn\/proqr-highlights-upcoming-presentation-at-20th-annual-meeting-of-the-oligonucleotide-therapeutics-society\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/english.saigonbiz.com\/vn\/"},{"@type":"ListItem","position":2,"name":"ProQR Highlights Upcoming Presentation at 20th Annual Meeting of the Oligonucleotide Therapeutics Society"}]},{"@type":"WebSite","@id":"https:\/\/english.saigonbiz.com\/vn\/#website","url":"https:\/\/english.saigonbiz.com\/vn\/","name":"Biz and Live in Saigon","description":"","publisher":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/english.saigonbiz.com\/vn\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/english.saigonbiz.com\/vn\/#organization","name":"SaigonBiz Media","url":"https:\/\/english.saigonbiz.com\/vn\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/","url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png","contentUrl":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png","width":512,"height":512,"caption":"SaigonBiz Media"},"image":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/SaigonbizGroup"]},{"@type":"Person","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6","name":"admin","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/image\/","url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png","contentUrl":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png","caption":"admin"},"sameAs":["https:\/\/english.saigonbiz.com\/vn"],"url":"https:\/\/english.saigonbiz.com\/vn\/profile\/admin\/"}]}},"_links":{"self":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts\/60276","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/comments?post=60276"}],"version-history":[{"count":0,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts\/60276\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/media\/60277"}],"wp:attachment":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/media?parent=60276"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/categories?post=60276"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/tags?post=60276"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}